BRISTOL MYERS SQUIBB
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-01-13
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 150
- Registration Number
- NCT00101608
- Locations
- 🇹🇭
Local Institution, Bangkok, Thailand
🇨🇦Local Insitution, Toronto, Ontario, Canada
Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer
Phase 2
Terminated
- Conditions
- First Posted Date
- 2004-12-22
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00099879
- Locations
- 🇳🇱
Local Insitution, Groningen, Netherlands
🇬🇧Local Institution, Manchester, United Kingdom
Phase I (PH I) Mad Refractory Solid Tumor Study
- First Posted Date
- 2004-12-20
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 60
- Registration Number
- NCT00099606
- Locations
- 🇬🇧
Local Institution, Glasgow, Strathclyde, United Kingdom
BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-11-23
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1238
- Registration Number
- NCT00097357
- Locations
- 🇵🇷
Local Institution, Ponce, Puerto Rico
Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection
- First Posted Date
- 2004-11-16
- Last Posted Date
- 2010-08-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 69
- Registration Number
- NCT00096785
- Locations
- 🇹🇭
Local Institution, Bankok, Thailand
🇺🇸Local Insitution, New York, New York, United States
Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access Program
- Conditions
- First Posted Date
- 2004-11-16
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00096811
- Locations
- 🇮🇱
Local Institution, Zefat, Israel
Effect of the Atazanavir (ATV) 150L Mutation on Subsequent Treatment Response in HIV Infected Subjects
- First Posted Date
- 2004-11-16
- Last Posted Date
- 2011-04-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 200
- Registration Number
- NCT00096746
- Locations
- 🇿🇦
Local Institution, Rugby, Western Cape, South Africa
🇺🇸Local Instution, Lexington, Kentucky, United States
A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1200
- Registration Number
- NCT00095758
- Locations
- 🇺🇸
Local Institution, Middleton, Wisconsin, United States
A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1200
- Registration Number
- NCT00095823
- Locations
- 🇺🇸
Local Institution, Middleton, Wisconsin, United States
Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-11-08
- Last Posted Date
- 2011-04-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 496
- Registration Number
- NCT00095550
- Locations
- 🇷🇺
Local Institution, St. Petersburg, Russian Federation
© Copyright 2024. All Rights Reserved by MedPath